Bloomberg -- Roche Holding AG’s Avastin failed to win the backing of the U.K. National Institute for Health and Clinical Excellence against breast cancer that has spread. The medicine’s “limited and uncertain benefit” when added to a type of chemotherapy called taxane is too small to justify the cost, the agency said today in an e-mailed statement. NICE advises the U.K.’s National Health Service on cost-effective treatments.
